Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 76

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Epilepsy

Not recruiting

Evaluation of 18F-DPA-714 PET-MRI imaging for locating epileptic focus in patients with drug-resistant partial epilepsy before surgery

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:N,N-Diethyl-2-(2-(4-(2[(18)F]-Fluoroethoxy)Phenyl)5,7Dimethylpyrazolo[1,5A]Pyrimidin-3-Yl)Acetamide
  • Sponsor:Commissariat a l'Energie Atomique et aux Energies Alternatives

Rabies

Not recruiting

Study Comparing Intradermal and Intramuscular Rabies Vaccination with Inactivated Rabies Virus for Patients Needing a Booster Dose

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Institute Of Tropical Medicine

Obesity+1

Not recruiting

Study on Rimegepant and Capsaicin for Migraine in Lean and Obese Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Capsaicin
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Cognitive disorder

Not recruiting

Study on the Effects of Donepezil on Cognitive and Motor Functions in Elderly Patients with Neurological Disorders

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Donepezil Hydrochloride
  • Sponsor:Carl Von Ossietzky Universitaet Oldenburg

Myasthenia gravis

Not recruiting

Study on the Effects of Remibrutinib for Patients with Generalized Myasthenia Gravis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Postural orthostatic tachycardia syndrome

Not recruiting

Study on the Effectiveness of Human Normal Immunoglobulin for Adults with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Plasma Protein
  • Sponsor:CSL Behring LLC

Study on the Safety and Effects of NPI-001 (Acetylcysteine Amide) for Patients Aged 50-85 with Mild Cognitive Impairment or Mild Alzheimer's Disease

Not recruiting
Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine Amide
  • Sponsor:Arctic Therapeutics ehf.

MELAS syndrome

Not recruiting

Study on the Safety and Effectiveness of Zagociguat for Treating MELAS in Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zagociguat
  • Sponsor:Tisento Therapeutics Inc.

Severe myoclonic epilepsy of infancy

Not recruiting

Study on the Effects of Bexicaserin for Treating Seizures in Children and Adults with Dravet Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Longboard Pharmaceuticals Inc.

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Safety and Effects of NVG-2089 for Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:NVG-2089
  • Sponsor:Nuvig Therapeutics Inc.

MELAS syndrome

Not recruiting

Long-term safety study of zagociguat tablets in patients with MELAS syndrome (Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) who completed previous trial

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zagociguat
  • Sponsor:Tisento Therapeutics Inc.

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.